Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SToP-C: Vortioxetine for Cannabis Use Disorder
NCT03485274Phase 3Completed
- Sponsor
- The University of Hong Kong
- Start
- Jul 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vortioxetine in cannabis use disorder (CUD), major depressive disorder (MDD), anxiety disorder, sponsored by The University of Hong Kong. Started Jul 2018; status: completed.
02
Drugs
vortioxetine
03
Conditions
cannabis use disorder (CUD)major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT03485274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485274.